Agios Pharmaceuticals Inc. (Nasdaq: AGIO) withdrew its investigational new drug application for AG-519 and will no longer develop its second pyruvate kinase-R activator. The stock price plummeted $10.86 to close at $45.08.
Agios Pharmaceuticals withdraws application
December 16, 2016 at 16:13 PM EST
